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Abstract: Oceans have borne most of the biological activities on our planet. A number of 
biologically  active  compounds  with  varying  degrees  of  action,  such  as  anti-tumor,  
anti-cancer,  anti-microtubule,  anti-proliferative,  cytotoxic,  photo  protective,  as  well  as 
antibiotic and antifouling properties, have been isolated to date from marine sources. The 
marine  environment  also  represents  a  largely  unexplored  source  for  isolation  of  new 
microbes (bacteria, fungi, actinomycetes, microalgae-cyanobacteria and diatoms) that are 
potent producers of bioactive secondary metabolites. Extensive research has been done to 
unveil the bioactive potential of marine microbes (free living and symbiotic) and the results 
are amazingly diverse and productive. Some of these bioactive secondary metabolites of 
microbial origin with strong antibacterial and antifungal activities are being intensely used 
as antibiotics and may be effective against infectious diseases such as HIV, conditions of 
multiple bacterial infections (penicillin, cephalosporines, streptomycin, and vancomycin) 
or neuropsychiatric sequelae. Research is also being conducted on the general aspects of 
biophysical  and  biochemical  properties,  chemical  structures  and  biotechnological 
applications of the bioactive substances derived from marine microorganisms, and their 
potential use as cosmeceuticals and nutraceuticals. This review is an attempt to consolidate 
the  latest  studies  and  critical  research  in  this  field,  and  to  showcase  the  immense 
competence of marine microbial flora as bioactive metabolite producers. In addition, the 
present  review  addresses  some  effective  and  novel  approaches  of  procuring  marine 
microbial compounds utilizing the latest screening strategies of drug discovery. 
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1. Introduction 
Microorganisms, including certain bacteria, fungi and algae, produce secondary metabolites which 
may have some degree of bioactivity, either against another microorganism or acting against certain 
physiological states of a diseased body. These metabolites, otherwise known as bioactive substances, 
are profoundly used as antibiotics and may be effective against infectious diseases such as HIV-1 [1]; 
conditions  of  multiple  bacterial  infections  (penicillin,  cephalosporines,  streptomycin,  and 
vancomycin); or neural tube defects and neuropsychiatric sequelae [2,3]. Some drugs have also been 
found to be useful against carcinomas (bleomycin, dactinomycin, doxorubicin and staurosporin), risk 
of  coronary  heart  disease,  or  may  act  as  immune-suppressants  (cyclosporin)  to  aid  in  organ 
transplantation  [4];  thus  making  the  microbial  secondary  metabolites  an  enormous  source  of 
pharmaceutical importance. Since the 1920s when the first antibiotic Penicillin was discovered, it was 
believed that soil microorganisms  are the largest  source of novel  drugs.  It  is  their biological  and 
chemical diversity, coupled with the underlying competence to produce novel secondary metabolites 
with antimicrobial and nutritive effects, that has led to the widespread use of microorganisms in the 
economic, industrial scale production of drugs. 
The ocean is the mother of life and it is believed that the most primitive forms of life originated 
from this “primordial soup”. It harbors a vast variety of marine organisms that are diverse in their 
physiology  and  adaptations.  These  marine  inhabitants  have  served  as  a  model  for  various  studies 
ranging from the deep knowledge about nerve transmission (squid and its giant nerve axons) to the 
mesenteries of vision (eyes of horseshoe crabs, sharks and skates). The surf clam is being used as an 
excellent model for the cell cycle and its regulation while the sea urchin is a model for understanding 
the molecular basis of cellular reproduction and development [5]. As they thrive in a different kind of 
climate, these organisms develop certain adaptation mechanisms which may be useful for their defense 
and the result of these adaptations may be useful for human beings in many  forms. Production of 
bioactive metabolites is one such adaptation mechanism, which helps in survival from predators. Some 
of the bioactive compounds from marine sources will be dealt with in detail later in this review. 
It is noteworthy that marine sources have also demonstrated tremendous abilities as producers of 
anti-cancer  compounds  and  secondary  metabolites  which  act  against  infectious  diseases  and 
inflammation.  Blunt  et  al.  (2004)  listed  that  in  marine  environment  sponges  (37%),  coelenterates 
(21%) and microorganisms (18%), are major sources of biomedical compounds, followed by algae 
(9%), echinoderms (6%), tunicates (6%), molluscs (2%) bryozoans (1%), etc. [6]. However, marine 
microorganisms have not been given the attention they deserve and a very limited insight into the 
capabilities and bioactive potential of marine microorganisms is available in literature to date. There is 
still scope for a higher magnitude of research and investigation to explore the potential of both marine 
organisms and marine microorganisms as producers of novel drugs. Apart from synthetic products, Mar. Drugs 2010, 8                            
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pharmaceutical industries in most of the developed and developing countries are now concentrating on 
natural products derived from marine microorganisms (Table 1).  
Table 1. Structure and biological activity of some of the marine microbial metabolites. 
Microorganism  Compound  Biological activity  Reference 
Cyanobacteria 
Dolastatin 10 
N
O
H
N
N
N H
N N
S
O O O O
O
 
Antimicrotubule; and the 
synthetic analogue,  
TZT-1027, as antitumor 
[7]  Dolastatin 15 
 
Antimicrotubule; and the 
synthetic analogue,  
ILX-651, as antitumor 
Curacin A 
CH3
N
S
CH3
H H
O
Me
 
Antimicrotubule 
Toyocamycin 
N
N N
O
OH OH
HO
NH2 NC
 
Antifungal 
[8] 
 
Actinomycetes 
Resistoflavine 
O OH OH
O
OH
O
OH
 
Anticancerous and 
antibacterial 
[9] 
Marinomycin A 
O
O
OH OH OH O
OH OH OH O
OH
HO
HO
OH
 
Antitumor and antibiotic 
[10] 
 
Daryamide C 
H
N
O
H2N
O
HO
O
 
Antitumor  [11] 
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Table 1. Cont. 
Violacein 
HN
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O
HO
 
Antiprotozoal  [12] 
Bacteria 
Macrolactin S 
O O
HO
HO
HO
OH
 
Antibacterial  [13] 
Pyrone I and II 
O
O
OH n  
Antibacterial  [14] 
MC21-B 
O O
OH HO
H H H H
Br Br H Br  
Antibacterial  [15] 
Fungi 
Meleagrin 
N
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O
HN
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O
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Antitumor  [16] 
Oxaline 
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Antitumor  [17] 
Alternaramide 
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N
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O
N
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O
O
O  
Antibacterial  [18] 
Algae 
Norharman  
H
N
N
 
Enzyme inhibitor   [19] 
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Table 1. Cont. 
Calothrixin-A 
N
H
N O
O
O
 
Antimalarial and 
anticancerous 
[20] 
Eicosapentanoic 
acid (EPA) 
H3C COOH
  Treats heart disease, Anti 
inflammatory agent 
(rheumatoid arthritis and 
immunodeficiency 
diseases)  
[21] 
Symbiotic microbes 
Macrolactin V 
O O
HO
HO
HO
OH
 
Antibacterial and 
antilarval 
[22] 
DAPG  
OH
CH3 H3C
HO
O O OH
 
Antibacterial  
(anti-MRSA, anti-VRSA 
and anti-VRE) 
[23] 
BE-43472B 
O
O
O
H3C
H
H3C
HO
OH O OH
O
CH3
OH
 
Antibacterial  
(anti-MRSA and  
anti-VRE)  
[24] 
This  review  focuses  on  the  tremendous  potential  of  marine  microbes  as  prolific  producers  of 
bioactive substances and discusses the possible ways to exploit the vast marine microbial treasure for 
their utilization as novel drug delivery systems. 
2. Marine Environment as a Prolific Source of Bioactive Compounds 
The Primordial Soup Theory suggests that life began in a body of water, possibly a pond or ocean 
when the chemicals from the atmosphere combined with some form of energy. This combination gave 
rise to the building blocks of proteins- the amino acids and may have led to the evolution of new 
species. Hence, oceans may be considered to be rich in organic compounds favorable for the evolution 
and growth of life in general. It was in the early 1960s that researchers began to concentrate on oceans 
as a novel and unexplored source of potentially useful bioactive compounds. The basis of this could be 
the fact that more than 95% of the Earth‟s biosphere is ocean [25] and scientists wish to unearth 
bioactive compounds in unexpected places as the antibiotic resistance increases and the production of Mar. Drugs 2010, 8                            
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novel bioactive compounds tapers down. As a result, more than 10,000 marine metabolites have been 
isolated and characterized over the past five decades [26].  
Rajaganapathi and colleagues (2002) purified and characterized an anti-HIV protein (MW 60 KDa) 
from the purple fluid of a sea hare and named it "Bursatellanin-P" after the animal species Bursatella 
leachii. This protein was resistant to digestion by proteinase K and mercaptoethanol [27]. Another 
report on the antiviral activity of a marine microorganism was published in 2006. Wang et al. (2006) 
observed that serum hepatitis B surface antigen was significantly lowered in Styela plicata treated 
mice compared with mice receiving a normal diet. They concluded that S. plicata may be an effective 
antiviral medicine in treating chronic hepatitis B [28]. 
Most of the Earth‟s microbial diversity is found in the ocean, which ultimately directs an enormous 
number  of  bioactive  substances  (Figure  1).  The  various  inhabitants  of  the  marine  environment 
including bacteria, fish, algae, corals, crustaceans and even sea mud are known to have tremendous 
potential to be utilized as cosmeceutical agents [29]. Recently, Ryu et al. (2009) demonstrated that 
methanol extracts of alga Corallina pilulifera possessed a high phenolic content, which reduced the 
expression of UV-induced MMP-2 and -9, in human dermal fibroblast in a dose dependent manner, 
thereby attaining the capability of inhibiting free radicals [30]. There has been another study on the 
photoprotective effect of phlorotannins from Ecklonia cava against the photo-oxidative stress induced 
by UV-B irradiation [31].  
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OH HO
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According  to  their  postulations,  among  the  isolated  phlorotannins,  dieckol  sho wed  prominent 
inhibitory activity against melanogenesis and effectively reduced UV -B radiation-induced cellular 
damage, which further indicated that dieckol from E. cava can be used as an effective natural source to 
make cosmeceutical or pharmaceutical products.  
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Figure 1. Diversity of bioactive substances produced in the marine environment. 
 
3. Marine Microorganisms as Producers of Bioactive Compounds 
Microbiology has developed as a great field of science in the recent past with microorganisms being 
used in almost all arenas. For the past five decades or more, it is the soil micro biota that has been 
subjected to extensive investigation all over the globe. One good reason for this may be the ease of 
microbial isolation from lithosphere compared to any other spheres of earth. Owing to the vast variety 
of  novel  chemical  compounds  from  these  microbes,  millions  of  strains  have  been  employed  for 
pharmacological screening. This is now changing as the rate of development of novel drug agents has 
slowed down and most of the terrestrially isolated microbial chemical formulations appear repetitive, 
and are further proving to be costly. 
A unique source in the world‟s oceans, the deep ocean and the geothermal vents, is now becoming 
the focus  of considerable microbiological  interest [32]. Marine micro biota does  not  only lead in 
quantitative  measures,  but  also  has  tremendous  potential  to  represent  a  biomedical  resource  of 
unknown  magnitude  and  great  promise.  Presence  of  obligate  barophiles,  bacteria  which  require 
pressures as high as 600 atmospheres for growth has been reported in recent past from the deep sea 
environment [33]. As certain classes of microbes have unique adaptations for high salt environments 
and high hydrostatic pressure, the immense miscellany of the microorganisms in marine habitats is 
quite perceptible. In addition, Inagaki et al. (2006) reported that previously unidentified prokaryotic 
communities such as the JS1 and DSAG groups occur widely in organic rich deep marine sediments 
associated with methane hydrates along the Pacific Ocean margin. They also suggested that microbial Mar. Drugs 2010, 8                            
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O
O O
O
Di-(2-ethylhexyl) phthalate 
communities can be stratified in deep marine sediments, and surrounding geochemical and geological 
settings strongly affect the community structure [34]. It is becoming more and more evident that many 
classes of microorganisms exist only in the sea.  
Due to limited literature on the culturing techniques and media formulation for culturing  marine 
microbes, pharmaceutical industries have not been able to  fully utilize this enormous resource. The 
myth still prevails that marine microorganisms are difficult to culture, if not uncultivable. However, a 
number  of  reports  in  recent  past  have  proven  that  marine  microorganisms  can  now  be  cultured  
successfully [25,35–37]. Most of the developed and underdeveloped countries have since shifted their 
focus to the marine habitat and new marine oriented programs are emerging worldwide. Major classes 
of  microbes  like  bacteria  and  fungi  are  now  the  target  of  biomedical  study  and  intriguing  novel 
metabolites are being produced. Coastal bacterial samples grown under saline conditions have been 
reported to yield new antibiotics, antitumor, and anti-inflammatory compounds [38–40]. In fact, the 
symbiotic microbial consortia also prove to be a source of bioactive compounds with pharmaceutical 
potential. Bacteria and fungi have been sampled from the surfaces of marine plants and the internal 
tissues of invertebrates and, in particular, marine fungi seem to be of increasing interest [41–45]. 
3.1. Marine bacteria 
Antagonism  is  nature‟s  own  counter  action  for  survival  and  existence.  Bacteria  produce  some 
secondary metabolites for their defense against other microorganisms and these secondary metabolites 
serve as a source of bioactive compounds for use in human therapies. Marine bacteria are prolific 
producers of such secondary metabolites as they thrive in harsh oceanic climates.  
Pseudomonas  are  gram-negative  Gammaproteobacteria  dwelling  on  lithosphere  as  well  as  in  a 
marine environment. Compared to terrestrial isolates, the marine isolates are not well explored and 
only a limited number have been reported as producers of bioactive compounds. In fact the exploration 
of  marine  environment  continues  for  isolation  of  more  novel  stains  of  Pseudomonas  which  are 
probable  sources  of  bioactive  compounds.  Recently,  Romanenko  et  al.  (2008)  have  isolated  and 
taxonomically  classified  an  aerobic,  nonpigmented  bacterium  strain  KMM 3042.  It  was  found  to 
cluster adjacent to P. borbori in the Pseudomonas genus, with 97% sequence homology. Although 
few, the chemical structures of these marine Pseudomonas derived bioactive substances are diverse, 
including  pyrroles,  pseudopeptide  pyrrolidinedione,  phloroglucinol,  phenazine,  benzaldehyde, 
quinoline, quinolone, phenanthren, phthalate, andrimid, moiramides, zafrin and bushrin [46]. Some of 
these  bioactive  compounds  are  antimicrobial  agents,  and  dibutyl  phthalate  and  di-(2-ethylhexyl) 
phthalate have been reported to be cathepsin B inhibitors [47]. 
 
 
 
 
 
 
 
 
O
O
O
O
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YP1 (Tambjamine) 
The  first  report  on  antimicrobial  activity  of  Stenotrophomonas  strains  isolated  from  deep  sea 
invertebrates came in 2008, stating that remarkable fungal inhibitory activity was observed  in six 
Stenotrophomonas  strains  isolated  from  sponge,  sea  urchin,  and  ophiura  specimens.  Although 
negligible activity was observed against Candida albicans, these strains could substantially inhibit 
Gram-positive microorganisms. It is worth noting here that S. maltophilia is an opportunistic pathogen 
known for its bio-controlling capabilities [48]. Another study from the same group, directed against 
low molecular weight antimicrobial metabolites from marine ark shell Anadara broughtoni associated 
heterotrophic bacteria, revealed antimicrobial, hemolytic and surface activities in butanol extracts of 
cells or cell-free supernatant of six active strains [49].  
Yet  another  recently  discovered  genus  of  bioactive  substance  producing  marine  bacteria  is 
Pseudoalteromonas. It was previously misclassified under Alteromonas genus and misidentified as 
Pseudomonas or Chromobacterium [50]. A couple of years ago, the seawater species P. phenolica was 
reported to inhibit methicillin resistant Staphylococcus aureus strains due to a brominated biphenyl 
compound, 3,3‟,5,5‟-tetrabromo-2,2‟-diphenyldiol [51]. Some strains of P. luteoviolacea also seem to 
have activity against protists [52]. Egan and coworkers (2002) reported that the yellow pigment of 
Pseudoalteromonas tunicata has anti-fungal activity [53] which was later identified as a tambjamine 
(4-methoxypyrrole-containing  bioactive  compounds)  like  alkaloid  and  designated  as  YP1  [54]  by 
Franks et al. (2005). These tambjamines have been isolated from marine invertebrates and have been 
previously reported to possess antimicrobial, antitumorigenic, immunosuppressive, anti-proliferative 
and ichthyodeterrent activities [55]. Evidence points towards the colonizing bacteria at the surface of 
higher organisms as the source of these compounds [56]. This has further been proven by Burke and 
colleagues by elucidation of YP1 biosynthetic pathway in P. tunicata [57]. 
NH
N
Me
HN
 
 
 
Bacterial polysaccharides are another class of pharmaceutically important secondary metabolites. It 
has been found that exopolysaccharides (EPS) from marine bacteria contain novel formulations with a 
variety of properties like thickening, coagulating, adhesion, stabilizing and gelling, which makes them 
suitable candidates for industrial applications. Moreover, good viscosity  and pseudoplastic properties 
of EPS render them resistant to the extr emities of temperature, pH and salinity making them more 
industry friendly [58]. In a recent study, an EPS-2 having immunomodulatory and antiviral effects on 
immunocompetent cells, has been reported from  Geobacillus  thermodenitrificans  obtained  from  a 
shallow marine vent of Volcano Island (Italy) [59]. 
Bacteria not only produce secondary metabolites against other organisms, but they also produce 
certain compounds which help in cleaning  their environment. Certain  marine bacterial species are 
known as prolific producers of biosurfactants, bioemulsifiers and exopolysaccharides. Das et al. (2008) Mar. Drugs 2010, 8                            
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studied the degradation of a model polyaromatic hydrocarbon, anthracene, an organic pollutant, by a 
marine Bacillus circulans strain. In addition, the produced biosurfactant depicted a high degree of 
emulsification of various hydrocarbons. It was observed that this bacterium utilized anthracene as a 
carbon  substrate  for  the  production  of  biosurfactant  [60].  This  group  also  investigated  another 
biosurfactant  producing  marine  bacterium  with  an  ability  to  remove  metal  from  solutions  with 
efficiency dependent on the concentration of the metal as well as on the biosurfactant [61].  
3.2. Marine fungi 
Marine derived fungi have been widely studied for their bioactive metabolites and have proven to 
be a rich and promising source of novel anticancer, antibacterial, antiplasmodial, anti-inflammatory 
and  antiviral  agents  [62,63].  Some  marine  fungi  have  unique  new  carbon  frameworks  which  are 
exceptional in nature. Compounds produced by such fungi are of interest as new lead structures for 
medicine as well as for plant protection. Responding to the great demand for natural compounds from 
marine  derived  fungi,  Kjer  et  al.  (2010)  have  defined  a  detailed  protocol  for  their  isolation  and 
cultivation  from  various  marine  organisms  (sponges,  algae  and  mangrove  plants)  in  order  to 
characterize and elucidate the structure of secondary metabolites produced by these fungi [64]. A 
couple  of  years  ago,  Du  et  al.  (2007)  isolated  a  novel  anthraquinone  derivative  with 
naphtho[1,2,3-de]chromene-2,7-dione skeleton, and named it aspergiolide A. It was isolated from a 
marine filamentous fungus, Aspergillus glaucus in the Fujian province of China, and was found to 
exhibit cytotoxicity against K562 and P388 cell lines [65]. The same group has recently worked on the 
antitumor activities of alkaloids isolated from a Penicillium sp. derived from deep ocean sediment. 
They  isolated  two  new  meleagrin  analogs,  meleagrin  D  and  E,  and  two  new  diketopiperazines, 
roquefortine  H  and  I  which  showed  weak  cytotoxicity  as  compared  to  the  previously  reported 
meleagrin B and meleagrin that induced HL-60 cell apoptosis or arrested the cell cycle through G2/M 
phase, respectively. They proposed that the distinct substitutions on the imidazole ring could have a 
significant influence on the cytotoxicity of these alkaloids [16]. 
A number of novel compounds and metabolites with bioactive potential continue to be isolated and 
characterized from marine derived fungi, which are capable of producing not only antimicrobial but 
also antifouling compounds. In 2006, a bioassay-guided isolation and purification procedure was used 
to obtain a novel antifouling and antimicrobial compound from a marine-derived fungus Ampelomyces 
sp. The isolate, 3-chloro-2,5-dihydroxybenzyl  alcohol effectively inhibited larval  settlement  of the 
tubeworm Hydroides elegans and of cyprids of the barnacle Balanus amphitrite and was non-toxic; 
suggestive of a potent antifoulant and/or antibiotic activity[66].
 Another study from the same group 
concerned  the  antibiotic  and  antifouling  compound  production  by  the  marine  derived  fungus 
Cladosporium sp. F14. They reported that in nutrient enriched cultivation media, this strain produced 
antibiotic and antifouling compounds in the presence of glucose or xylose [67]. In the search for novel 
antimitotic and antifungal substances from marine-derived fungi, Gai and coworkers (2007) reported 
that low concentration of the EtOH extracts of the culture broth of a Fusarium sp. (strain 05JANF165) 
were bioactive. Their search for the basis of this bioactivity led to the identification and purification of 
a new antifungal antibiotic and the chemical structure was elucidated as Fusarielin E [68].  Mar. Drugs 2010, 8                            
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A  Korea  bas ed  study  resulted  in  the  isolation  of  a  novel  antibacterial  dioxopiperazine, 
dehydroxybisdethiobis-methylthio-gliotoxin,  and  the  previously  r eported  bisdethiobis-methylthio-
gliotoxin and gliotoxin, from the broth of a marine derived fungus of the genus Pseudallescheria and 
its structure was assigned through NMR. All three compounds exhibited potent antibacterial activity 
against  the  methicillin  resistant  and  multidrug  resistant  Staphylococcus  aureus,  whereas  Gliotoxin 
showed a significant radical scavenging activity against 1,1-diphenyl-2-picrylhydrazyl (DPPH) with 
IC50 value of 5.2 µM [69].  
 
 
 
 
 
 
(1) Dehydroxybisdethiobis(methylthio)gliotoxin and  
(2) bisdethiobis(methylthio)gliotoxin  
 
Another study from the same source, reported two novel antibacterial aspyrone derivatives viz. 
Chlorohydroaspyrones A and B, and the previously described aspyrone, asperlactone, and penicillic 
acid  from  the  broth  of  a  marine  isolate  of  the  fungus  Exophiala  and  were  found  to  have  mild 
antibacterial activity against Staphylococcus aureus [70].  
O
HO
Cl
O
OH
O
HO
OH
O
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Marine fungi have also been reported to have  a nematicidal effect, for example, nematicidal and 
antimicrobial metabolites were reported  previously from marine ascomycete  Lachnum papyraceum 
(Karst.) Karst III and the production of novel isocoumarin derivatives was achieved under halogenated 
Chlorohydroaspyrones 
A  B 
1)  R=H 
2)  R=OH 
N N
OH
SMe
SMe
Me
O
O
R
H
Gliotoxin 
N
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Mansouramycin 
D 
Lucentamycin A 
conditions  [71].  Inspired  by  this  work,   Nenkep  et  al.  (2010)  recently  reported  the  isolation  of 
halogenated  benzoquinones  (bromochlorogentisylquinones  A  and  B),  with  significant  radical 
scavenging activity against DPPH, from a marine derived Phoma herbarum strain [72].  
O
O
O
O
Br
OH Cl
Br
OH
Cl
 
 
 
3.3. Actinomycetes 
Actinomycetes  from  natural  sources  are  widely  recognized  to  produce  secondary  metabolites, 
including many antimicrobials such as streptomycin, erythromycin, and tetracycline, with original and 
ingenious structures and potent biological activities [73]. Therefore, actinomycetes are considered to 
be  a  potent  resource  for  new  lead  compounds  in  drug  development.  Many  marine  isolates  of 
actinomycetes  have  been  reported  to  be  producers  of  novel  antitumor  [74],  antimalarial  [75]  and 
antimicrobial agents [76,77].  
In the exploration of marine derived actinomycetes as a source of antitumor compounds, Cho et al. 
(2007) isolated four new 3-methyl-4-ethylideneproline-containing peptides, Lucentamycins A-D from 
the fermentation broth of a marine derived actinomycete, Nocardiopsis lucentensis (strain CNR-712). 
Out  of  the  four  compounds,  Lucentamycins  A  and  B  were  observed  to  have  significant  in  vitro 
cytotoxicity  against  HCT-116  human  colon  carcinoma  [78].  In  a  report  published  last  year,  five 
isoquinoline  quinones,  four  new  derivatives,  Mansouramycin  A-D,  and  the  known  3-methyl-7-
(methylamino)-5,8-isoquinolinedione  were  isolated  from  the  ethyl  acetate  extract  from  the  marine 
derived Mei37 isolate of Streptomyces sp. These isolated compounds, when subjected to cytotoxicity 
analysis against 36 tumor cell lines, indicated significant cytotoxicity with great degree of selectivity 
for non-small cell lung cancer, breast cancer, melanoma, and prostate cancer cells [79] suggesting their 
potential as anticancer drugs.  
H
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O
O N
NH
HO
O
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NH
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In the same year, Perez and coworkers isolated a macrodiolide Tartrolon D from the fermentation 
broths  of  Streptomyces  sp.  MDG-04-17-069.  The  tartrolons  are  a  class  of  compounds  that  have 
Bromochlorogentisylquinones 
A  B Mar. Drugs 2010, 8                            
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Tartrolon D  Lodopyridone 
attracted a great deal of attention owing to their interesting biological properties. The isolated tartrolon 
in this study was found to display strong cytotoxic activity against three human tumor cell lines  viz. 
lung (A549), colon (HT29), and breast (MDA-MB-231) [80]. Yet another study reported the secondary 
metabolites of a marine Saccharomonospora sp. collected at the La Jolla Submarine Canyon. Chemical 
examination  yielded  a  novel  alkaloid  Lodopyridone,  which  was  found  to  be  cytotoxic  
(IC50 = 3.6 µM) to HCT-116 human colon cancer cells [81]. 
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Marine actinomycetes are not only known for their anti-tumor and anti-cancerous potential, they are 
well documented as antimicrobial agents too. A California based study was successful in isolating a  
series of chlorinated bisindole pyrroles, Lynamicins A–E from a novel strain of a marine actinomycete, 
Marinispora. This isolate from marine sediment collected off the coast of San Diego (California) 
demonstrated  broad-spectrum  activity  against  both  Gram-positive  and  Gram-negative  organisms. 
When  tested  for  their  antimicrobial  spectrum  against  a  panel  of  11  pathogens,  these  compounds 
showed activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus 
and vancomycin-resistant Enterococcus faecium [77]. Carlson et al. (2009) have reported the isolation 
of novel dienoyl tetramic acids tirandamycin C and tirandamycin D with activity against vancomycin-
resistant Enterococcus faecalis, from the marine environmental isolate Streptomyces sp. 307-9. These 
compounds were structurally similar to the previously identified compounds Tirandamycins A and B 
with a slight variation in the pattern of pendant oxygenation on the bicyclic ketal system [82].  
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Maskey et al. (2004) isolated Trioxacarcins A, B and C along with three new derivatives designated 
as Trioxacarcins D, E and F, from the ethyl acetate extract of Streptomyces sp. isolate B8652. All 
trioxacarcins showed high anti-bacterial activity whereas some of them showed high anti-tumor and 
anti-malarial activity [83]. In a latest study, crude extract of a marine Streptomyces strain obtained 
from deep sea sediments, was used to isolate five structurally similar compounds which were found to 
have potent antifouling activity [84].  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
On the other hand, a marine-derived Actinomyces strain (NPS554) isolated from Japan yielded two 
trialkyl-substituted aromatic acids, Lorneic acid A and Lorneic acid B. It was observed that Lorneic 
acid A had significant inhibition activity against phosphodiesterase (PDE) 5 [85]. It is worth noting 
here that PDE5 inhibitors are of pharmacological importance in erectile dysfunctions and pulmonary 
hypertension. 
 
 
 
 
3.4. Microalgae 
Cyanobacteria are a diverse group of Gram-negative bacteria, also known as blue-green algae that 
produce an array of secondary compounds with selective bioactivity against vertebrates, invertebrates, 
plants, microalgae, fungi, bacteria, viruses and cell lines [86]. Some reviews in the past have proved 
that they produce a wide variety of secondary metabolites with antifungal, antiviral, antibiotic and 
other activities,  which make them an interesting candidate of potential pharmaceutical  importance 
[87,88].  Certain  anticancer  compounds,  which  were  initially  thought  to  be  obtained  from  marine 
sources, are now known to be produced by cyanobacteria [89]. Ulithiacyclamide and Patellamide A 
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belong to Cyanobactins, produced by cyanobacteria, which have potent antimalarial, antitumor, and 
multidrug reversing activities [90].  
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Recently, two new bioactive marine cyanobacterial natural products, Viridamides A and B, linear 
lipopeptides  with  a  terminal  acetylene  group  and  novel  terminal  proline  methyl  ester  and  a 
5-methoxydec-9-ynoic acid moiety, have been reported. It was observed that Viridamide A showed 
anti-trypanosomal activity with an IC50 of 1.1 μM and anti-leishmanial activity with an IC50 of 1.5 μM. 
The producer organism being blackish-green, mat-forming, filamentous cyanobacterium identified as 
Oscillatoria  nigro-viridis  [91].  Green algae have also  been reported as producers of antiprotozoal 
molecules. In a recent study , Allmendinger et al. (2010) screened the antiprotozoal activity of crude 
extracts of four green marine algae (Cladophora rupestris, Codium fragile sp. tomentosoides, Ulva 
intestinalis  and  Ulva  lactuca).  All  algal  extracts  showed  antiprotozoal  activity  against  T.  brucei 
rhodesiense, and leishmanicidal activity with IC50 values ranging between 12.0 and 20.2 μg/mL [92]. 
This study was reportedly the first study to show antiprotozoal activity of British marine algae.  
 
 
 
 
 
 
 
 
Diatoms are microscopic unicellular marine colonial algae belonging to the Diatomaceae family and 
having a siliceous very delicate covering [93]. In view of the growing concern for multidrug resistant 
bacterial strains, novel marine natural products from diatoms are being sought to combat this critical 
situation. Desbois et al. (2009) isolated an antibacterial polyunsaturated fatty acid, eicosapentaenoic 
acid  (EPA)  from  the  marine  diatom,  Phaeodactylum  tricornutum  Bohlin,  which  showed  activity 
against a range of both Gram-positive and Gram-negative bacteria, including MRSA [94].  
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3.5. Marine viruses 
Viruses are typically viewed as pathogens that cause disease in animals and plants. In recent years 
however, it has become increasingly clear that they play critical roles in the world‟s oceans. Not much 
is known about the bioactive potential of marine viruses but the focus is turning these days to discover 
newer  marine  viruses  and  to  study  their  physiological  processes  and  the  secondary  metabolites 
produced, if any. 
3.6. Symbiotic marine micro-organisms 
Study of symbiotic microorganisms is a rapidly growing field as some reports from the recent past 
suspect that a number of metabolites obtained from algae and invertebrates may be produced by their 
associated microorganisms [35,95–98]. Sponge associated microbes are known for their tremendous 
activities covering a wide range of biological functions [99]. Recently, Baker et al. (2009) carried out a 
study aimed at isolation and identification of a diverse range of fungi from H. simulans. They used 
varieties of media for identification and determination of antimicrobial activities, if any. They isolated 
19  different  genotypes  belonging  to  Agaricomycotina,  Mucoromycotina,  Saccharomycotina,  and 
Pezizomycotina; some of these isolates showing antimicrobial inhibition of Escherichia coli, Bacillus 
sp.,  Staphylococcus  aureus,  and  Candida  glabrata  [100].  The  sponge-microbial  association  is  a 
potential chemical and ecological phenomenon, which provides sustainable resource for developing 
novel  pharmaceutical  leads.  Keeping  in  view  the  importance  of  antimicrobial  potential  of  marine 
sponge  associated  microbes,  targeting  sponge  microsymbionts  is  an  essential  focus 
nowadays [101,102].  
A  marine  derived  fungal  strain  M-3,  isolated  from  marine  red  alga  Porphyra  yezoensis  was 
screened for its antifungal activity (MIC-0.36 µM) against Pyricularia oryzae by Byun et al. (2003). 
As a result, a novel Diketopiperazine was isolated from the culture extracts and its structure was also 
elucidated by spectroscopic methods. A study in 2004, reported hemolysis and inhibition of Candida 
albicans  by  employing  the  butanolic  extracts  of  the  algal  associated  species  Pseudoalteromonas 
issachenkonii cultures. Further analysis of the ethyl acetate extracts revealed that the basis of this 
antifungal activity was Isatin (indole-2,3-dione) [103].  
H
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A red-brown hemolytic pigment of 269 Da and corresponding to molecular formula C 9H7N3OS3 
was also discovered by the same group [104]. Apart from great ecological value from the habitat point 
of  view,  coral  reefs  are  the  most  species-rich  environments  in  the  oceans  harboring  a  number  of 
microbial species proving to be a rich and unexplored source of novel bioactive compounds [105].  Mar. Drugs 2010, 8                            
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Microbes  associated  with  a  number  of  marine  organisms  are  also  known  for  their  bioactive 
potential [36]. About 10 years ago, Tapiolas and coworkers (1991) isolated and characterized two 
closely related novel compounds, Octalactins A and B from a marine derived Streptomyces sp. isolated 
from the surface of an unidentified gorgonian of the genus Pacifigorgia. They reported that Octalactin 
A exhibited strong cytotoxic activity towards B-16-FlO murine melanoma and HCT-116 human colon 
tumor cell lines with the IC50 values of 0.0072 and 0.5 pg/mL, respectively [106].  
 
 
 
 
 
 
 
 
On  similar  lines,  a  recent  study  reported  antibacterial  and  antilarval  compounds  from  marine 
gorgonian  associated  bacterium  Bacillus  amyloliquefaciens  SCSIO  00856  isolated  from  the  South 
China Sea gorgonian, Junceella juncea. The broth of this strain showed strong antibacterial activity 
towards Escherichia coli, Bacillus subtilis, and Staphyloccocus aureus and antilarval activity towards 
the larvae of bryozoan Bugula neritina. When subjected to isolation procedures, a new 24-membered 
ring lactone, Macrolactin V was obtained from the culture broth [22].  
Certain species of marine bacteria known as colonists of marine macro-organisms have also been 
reported to have antimicrobial potential. In a report, 42 strains of marine bacterial isolates showed 
antimicrobial  activity  and  were  assigned  to  genera  Alteromonas,  Pseudomonas,  Bacillus  and 
Flavobacterium [107]. Certain mycoparasitic and fungicolous fungi are known to colonize other fungal 
physiological structures and are known to be the source of effective bioactive agents [108–111]. A 
study conducted in the United States in 2002 reported five new natural products, Phomadecalins A, B, 
C and D, and Phomapentenone A, from cultures of Phoma sp. (NRRL 25697), a mitosporic fungal 
colonist isolated from the stromata of Hypoxylon sp. These compounds were characterized structurally 
and four compounds (phomadecalins A–D) were found to be active against Gram-positive bacteria, 
Bacillus subtilis (ATCC 6051) and Staphylococcus aureus (ATCC 29213) [112]. 
 
 
 
 
The saga of marine microbial bioactive metabolites is continuing with new compounds being added 
day by day. Our knowledge, however, is still a miniscule of what exists deep in the oceans. Since it is 
almost impossible to cover all the marine derived microbial bioactive substances in a single review, the 
representative chemical structures of some of the above mentioned secondary metabolites/bioactive 
substances have been presented.  Mar. Drugs 2010, 8                            
 
 
2690 
N
H
N
N
N
O
O
O
N
H
N
O O
Tasidotin 
4. Clinical Status of Marine Compounds of Microbial Origin  
The ultimate goal of the bioactivity driven drug discovery from marine sources is to discover newer 
and  effective  formulations  for  the  treatment  of  deadly  human  diseases.  The  first  defined  marine 
product to enter clinical trials for any major human disease was Didemnin B isolated from the tunicate 
Trididemnum solidum. Since then, a number of drugs such as Ara A (Vidarabine-Vira-A
®), Ara C 
(antiviral)  and  synthetic  analogue  of  Ara  C-  cytarabine  (Cytosar-U
®-anticancer)  have  successfully 
passed the trials to become clinically approved drugs of pharmaceutical importance [113]. Apart from 
this, Yondelis
®, otherwise known as Ecteinascidin 743, has been approved in Europe for the treatment 
of  soft  tissue  sarcoma  and  another  marine  bioactive  metabolite,  the  Conus  toxin,  also  known  as 
Ziconotide or Prialt
® has been approved safe for intractable pain [114]. 
Despite the vast diversity of microbial consortium in deep oceans and the plethora of bioactivity 
that they display, very few drugs of marine microbial origin are on the market. With an integrated 
approach of microbiology, screening and natural products chemistry, the marine microbial metabolites 
are now advancing to be pharmaceutically important drug candidates. Plinabulin (NPI-2358), a potent 
and  selective  vascular  disrupting  agent  (VDA)  initially  isolated  from  a  marine  fungal  extract  is 
presently undergoing Phase II clinical trials. Preclinical studies suggested this compound to be active 
against multi-drug resistant human tumor cell lines and it was observed to greatly enhance the efficacy 
when used in combination with the already existing chemo- or radio-therapy regimens in a variety of 
animal  models  [114,115]. Tasidotin,  Synthadotin  (ILX-651)  derived  from  a  marine  bacterium is  also 
under Phase II clinical trials with Genzyme Corporation (Cambridge, MA). Another bacterial peptide of 
marine origin, Soblidotin (TZT 1027), is undergoing Phase III clinical trials under the supervision of Aska 
Pharmaceuticals (Tokyo, Japan). Both of these compounds are promising anticancer agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One of the most sought after marine microbial drug candidates is Marizomib (Salinosporamide A; 
NPI-0052).  Salinosporamide  A  is  a  novel  proteasome  inhibitor  isolated  from  a  marine  bacterium 
Salinispora  tropica  [116]  and  is  undergoing  Phase  I  clinical  trials  under  the  aegis  of  Nereus 
Pharmaceuticals  (San  Diego,  CA).  Interesting  properties  such  as  a  broader  and  longer  lasting 
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proteasome inhibition, efficacy against a wider ra nge of hematologic malignancies  and many solid 
tumor models, less cytotoxicity to normal cells, higher in vivo potency and potential for both oral and 
intravenous  administration  makes  Salinosporamide  A  a  very  promising  anticancer  agent  [115]. 
Bryostatin 1 is a well known marine anticancer agent, initially thought to be produced by Bryozoa. 
However  recent  reports  have  confirmed  its  production  from  the  bacterial  symbiont,  Candidatus 
Endobugula sertula [117]. This compound is also under Phase I clinical trials with National Cancer 
Institute  (NIH,  U.S.)  [114].  Sorbicillactone-A  is  yet  another  antileukemic  agent  produced  by 
Penicillium  chrysogenum  associated  with  marine  sponge  Ircinia  fasciculata.  This  alkaloid  is  also 
known to have antiviral and neuroprotective properties [118]. Owing to its wonderful antileukemic 
properties, this compound has also qualified for human trials [119]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cyanobacteria produce a family of antitumor agents known as Cryptophycins, which interfere with 
the tubulin assembly. A synthetic cryptophycin derivative (LY355703, CRYPTO 52) is in the early 
stages  of  clinical  evaluation.  Depsipeptide  (NSC  630176)  is  a  bicyclic  peptide  isolated  from 
Chromobacterium  violaceum.  It  decreases  mRNA  expression  of  the  c-MYC  oncogene,  causes 
cell-cycle arrest at G0-G1 and acts as an inhibitor of a histone deacetylase. These properties make it a 
promising  anticancer  agent  for  which  the  Phase  I  clinical  trials  are  soon  to  begin  [120].  With 
augmenting focus of research in the field of marine biotechnology, novel and potent compounds of 
biomedical interest are being discovered from the ocean bed, at a speedy rate. The most efficient and 
bioactive substances would keep on qualifying for clinical trials to become successful drug candidates 
in future. 
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5. Future Perspectives and Concluding Remarks 
As evidenced from past and ongoing research, microbial consortium has an excellent plethora of 
bioactivity. A number of past reviews have focused the attention of researchers on this tremendous 
treasure of the marine microbial environment [25,35,36,95–98]. But there is still a long way to go. 
Although a diversified range viz., antibiotic, antifungal, cytotoxic, neurotoxic, antimitotic, antiviral, 
antineoplastic and antiprotozoal activity is known, extensive studies are still needed in the field of 
AIDS, immunosuppression, anti-inflammation, Alzheimer disease and ageing processes [121]. Efforts 
are needed to expand the marine microbes derived drug discovery to include other diseases, which 
need extensive and urgent attention in terms of new therapies. The approach needs to be more focused 
and organized to combat multi drug resistance and a serious threat of re-emerging infectious diseases, 
which is a growing concern in the medical fraternity. 
Interdisciplinary  research  and  collaborative  endeavors  are  required  amongst  scientists,  medical 
practitioners, marine microbiologists and biotechnologists, to provide innovative approaches to marine 
based biomedical research. As discussed in the introduction section, the marine organisms are already 
being used as biomedical models to understand the complexity of disease processes in humans [5], but 
the role of marine microbes in the same field has not been well explored. Knowledge about the exact 
mechanism of action of the microbial metabolites, cross talk between marine sciences and microbial 
biotechnology,  proper  understanding  of  the  chemical  interactions  in  the  oceanic  environment  and 
development of appropriate bioassays may be utilized for development of newer classes of marine 
microbes derived drugs. 
Advances have begun in the field of marine microbial biotechnology but a more extensive  and 
focused approach is needed to investigate what else the marine microbes have to offer. A recent report 
suggested the production of bioactive peptides from marine yeast Aureobasidium pullulans HN2-3. 
The peptides  produced  from  single-cell protein of marine  yeast  strain  G7a had  good  angiotensin-
converting enzyme inhibitory activity [122]. Thorough research in the field of bioactive peptides from 
marine microbes may open the gates for many future implications in the field of biomedical sciences. 
In fact, microbial biofilms also have a number of technological applications which could be looked 
into. Many signal transduction pathways involved in the production of marine microbial antifouling 
compounds can be worked out through a more specific research on biofilms. It is believed that once 
genetic regulation of the colonization process is better understood, chemicals can be identified and 
applied that will directly interfere with genetic transcription itself or inhibit or foster any step along the 
signal transduction pathway [123].  
As any other chemical  reaction or metabolic process, production of secondary metabolites also 
depends upon certain physico-chemical factors viz., amount of oxygen available, optimum temperature 
and  pH.  The  appropriate  maintenance  of  these  parameters  may  enhance  metabolite  production. 
Moreover, the pharmaceutical industry is now concentrating on traditional mutagenesis programs for 
strain and product yield improvement. Genetic engineering could prove to be a boon for improvement 
in the yield of bioactive metabolites as the biosynthetic pathways can now be manipulated through 
recombinant DNA technology. In addition, researchers are now trying for heterologous expression of 
biosynthetic gene clusters in other organisms, which would not only increase the production levels but Mar. Drugs 2010, 8                            
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also speed the process by using rapidly growing and easy to manipulate organisms compared to the 
producing organism [124]. 
It  is  worth  giving  serious  consideration  to  the  exploitation  of  marine  microbial  life  and  the 
associated  secondary  metabolites,  aided  by  genomic  analyses,  applying  metabolic  approach  and 
employing combined biomedical and biotechnological efforts, which would lead to discovery of some 
novel, lead compounds of a varied degree of bioactivity. The novel bioactive metabolites isolated and 
characterized from marine microbes would be useful in controlling human diseases and protecting 
human  health  by  solving  tribulations  associated  with  antibiotic  resistance.  Certain  bioactive 
metabolites may also be beneficial in ensuring environmental hygiene (antifouling compounds). The 
development  of  more  automated  and  more  affordable  techniques  for  isolating  and  characterizing 
marine  microbial  bioactive  metabolites  would  definitely  make  marine  microbial  natural  product 
extracts more accessible to natural products‟ chemists and make life more disease free and worth living 
for mankind. 
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